Phase 1 Recurrent Acute Lymphoblastic Leukemia Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRefractory Acute Lymphoblastic Leukemia+3 more
M.D. Anderson Cancer Center120 enrolled1 locationNCT02392572
Recruiting
Phase 1
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+12 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT07166419
Recruiting
Phase 1Phase 2
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center75 enrolled1 locationNCT03128034
Recruiting
Phase 1
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic Leukemia
City of Hope Medical Center24 enrolled1 locationNCT06447987
Recruiting
Phase 1
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital30 enrolled1 locationNCT06777979
Recruiting
Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088